AI Tool Allows Identification of Malignant Cells in Gliomas
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
THURSDAY, July 13, 2023 -- An artificial intelligence system can identify cancer cells and predict genetic mutation status of gliomas using intraoperative cryosection samples, according to a study published online July 7 in Med.
Noting that intraoperative cryosection evaluation remains the gold standard for guideline surgical treatments for gliomas, but that the tissue-freezing process often generates artifacts complicating histologic interpretation, MacLean P. Nasrallah, M.D., Ph.D., from the University of Pennsylvania in Philadelphia, and colleagues used samples from 1,524 glioma patients from three different patient populations to analyze cryosection slides and develop the context-aware Cryosection Histopathology Assessment and Review Machine (CHARM).
The researchers found that the CHARM models were able to identify malignant cells (area under the receiver operating characteristic curve [AUROC], 0.98 in the independent validation cohort), differentiate between isocitrate dehydrogenase (IDH)-mutant and wild type tumors (AUROC, 0.79 to 0.82), classify three main types of molecularly defined gliomas (AUROC, 0.88 to 0.93), and identify the most prevalent subtypes of IDH-mutant tumors (AUROC, 0.89 to 0.97). In addition, clinically important genetic alterations in low-grade glioma were predicted by CHARM, including ATRX, TP53, and CIC mutations, CHKN2A/B homozygous deletion, and 1p/19q codeletion via cryosection images.
"Right now, even state-of-the-art clinical practice cannot profile tumors molecularly during surgery," a coauthor said in a statement. "Our tool overcomes this challenge by extracting thus-far untapped biomedical signals from frozen pathology slides."
One author is an inventor on a patent, and a consultant for Curatio.DL.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2023
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.